Focus: MediWound is a publicly traded Israeli biotech specializing in enzymatic debridement and wound care therapeutics, with a focused pipeline in burn care and chronic wounds.
Profile data last refreshed 19h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow MediWound to get notified when they start hiring — the background below is worth knowing for when they do.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
FDA-approved lead product driving commercialization; Phase 3 trials ongoing for expanded burn indications suggest label expansion strategy.
Help build intelligence for MediWound
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from MediWound's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo